Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108979 · ClinicalTrials.gov registry record · Phase 3
Study of Escitalopram in Adult Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00108979 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 240 participants.
The verdict
NCT00108979, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy, safety, and pharmacoeconomics of escitalopram and an active comparator in patients with major depressive disorder.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108979
The ClinicalTrials.gov registry entry for NCT00108979 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT00108979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108979 about?
NCT00108979 is a clinical study titled "Study of Escitalopram in Adult Patients With Major Depressive Disorder". Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy, safety, and pharmacoeconomics of escitalopram and an active comparator in ...
What is the current status of trial NCT00108979?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2005-03. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00108979?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00108979?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.